Skyrizi Subcutaneous (pens or syringes) — Medica

Initial criteria

• age ≥ 18 years
• Patient meets ONE of the following: has tried at least one traditional systemic agent for psoriasis (e.g., methotrexate, cyclosporine, acitretin) for at least 3 months unless intolerant (a 3‑month trial of PUVA counts); OR has contraindication to methotrexate
• Medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has been established on the requested drug for at least 3 months
• Patient experienced a beneficial clinical response defined as improvement from baseline in at least one of: estimated body surface area, erythema, induration/thickness, and/or scale of affected areas
• Compared with baseline, patient experienced improvement in at least one symptom such as decreased pain, itching, and/or burning

Approval duration

Initial: 3 months; Reauthorization: 1 year